Insights Series – Evaluating Fenfluramine for CDKL5 Deficiency Disorder: Key Findings from a Phase 3 Trial

The discussion opens with a clinical overview of CDKL5 deficiency disorder, focusing on the severe seizure burden, associated developmental complications, and the ongoing limitations of current antiseizure treatment strategies.

Sam Amin, MD, reviews the design of the recent phase 3 fenfluramine study in CDKL5 deficiency disorder, highlighting patient eligibility, baseline seizure burden, concomitant medication use, and key efficacy endpoints.

Sam Amin, MD, reviews the primary and secondary efficacy findings from the phase 3 fenfluramine study in CDKL5 deficiency disorder, highlighting meaningful reductions in seizure burden and improvements in global functioning measures.

Epileptologist Sam Amin, MD, reviews the safety and tolerability findings from the phase 3 fenfluramine study in CDKL5 deficiency disorder, including treatment-emergent adverse events and the absence of major cardiovascular complications.

Sam Amin, MD, discusses how phase 3 findings may influence CDD treatment approaches, while emphasizing the need for long-term safety and efficacy data to better define fenfluramine’s role in clinical practice.